In a recent review published in Signal Transduction and Targeted Therapy, researchers presented recombinant adeno-associated virus (rAAV)-based genetic applications to treat human diseases. Study: ...

Safety issues linked to adeno-associated virus (AAV) gene therapies, including patient deaths tied to liver toxicity, are prompting developers to explore non-viral delivery methods. Alternatives such ...

Researchers have developed a novel version of a key CRISPR gene-editing protein that shows efficient editing activity and is small enough to be packaged within a non-pathogenic virus that can deliver ...

As gene and cell therapies mature, developers are increasingly looking beyond existing delivery systems to address challenges around targeting, immunogenicity, manufacturability, and cost. Dr. Angelo ...

Adeno-associated viruses (AAVs) are as small, replication-defective, non-enveloped viruses, serving as vectors for gene therapy. AAV vectors play a transformative role in delivering therapeutic genes ...

Affinia Therapeutics ("Affinia"), an innovative gene therapy company with a pipeline of first-in-class and/or best-in-class ...